RE:RE:RE:Insiders Continue to add sharesI think it is zero; the problem with the specialty pharma space in Canada is that the valuations are coming off a sugar high from about 5 or 6 years ago.
The valuations across the Board in Canada are cheap given their relatively optimistic outlooks including Knight, MDP, Bausch etc.,
Effectively we need to see consolidation in the space, this would help to raise valuations. But clearly the glory days of past are long gone.
It is curious though that management has not been more aggressive in their share buyback as there is clearly an overhang of stock.